Cytokinetics (CYTK) Tops Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $72.72 --0%
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi turns more bullish on trucking stocks
- Jefferies names five top tech picks after August reporting season
- H.C. Wainwright Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
